What we heard report - stakeholder consultation on the naming of biologic drugs. : H14-635/2019E-PDF
"Health Canada and the Institute for Safe Medication Practices (ISMP) Canada conducted an online consultation on the naming of biologic drugs from January 18 to February 9, 2018. With the entry of biosimilars into the Canadian market, the number of biologic drugs sharing a nonproprietary (common) name is increasing. The objectives of the consultation were (1) to seek stakeholder views on whether Health Canada’s current approach to biologics naming is adequate or, if not, which alternate proposed option would be most appropriate to distinguish among biologics that share the same non-proprietary name, and (2) to better understand the impact of implementing each proposed option on external stakeholders"--Introduction, page 2.
Lien permanent pour cette publication :
publications.gc.ca/pub?id=9.940342&sl=1
| Ministère/Organisme | Canada. Health Canada, issuing body. |
|---|---|
| Titre | What we heard report - stakeholder consultation on the naming of biologic drugs. |
| Type de publication | Monographie |
| Langue | [Anglais] |
| Autres langues publiées | [Français] |
| Format | Électronique |
| Document électronique | |
| Note(s) | Issued also in French under title: Rapport « Ce que nous avons entendu » – consultation auprès des intervenants sur l’attribution de noms aux médicaments biologiques. |
| Information sur la publication | [Ottawa] : Health Canada = Santé Canada, [2019] |
| Description | 1 online resource (8 pages) : chart |
| Numéro de catalogue |
|
| Descripteurs | Biologicals -- Canada -- Public opinion. Drugs -- Labeling -- Canada -- Public opinion. Public opinion -- Canada. |